Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
412 studies found for:    Open Studies | Interventional Studies | melanoma
Show Display Options
Rank Status Study
21 Recruiting Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
Condition: Melanoma
Interventions: Biological: Dose 1;   Biological: Dose 2;   Biological: Dose 3;   Biological: Dose 4
22 Not yet recruiting A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: PLX3397
23 Recruiting Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Condition: Melanoma
Intervention: Biological: Escalating Doses
24 Not yet recruiting Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Condition: Malignant Melanoma
Interventions: Drug: Vemurafenib;   Drug: Cobimetinib;   Drug: Atezolizumab
25 Recruiting Neurotropic Melanoma of the Head and Neck
Condition: Melanoma
Interventions: Other: Observation;   Radiation: Radiation Therapy
26 Not yet recruiting MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients
Condition: Melanoma
Interventions: Drug: Propranolol;   Drug: Placebo
27 Recruiting Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Condition: Melanoma
Interventions: Drug: High-dose Interferon alfa-2b;   Drug: Vemurafenib
28 Recruiting Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Drug: Axitinib
29 Not yet recruiting M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma
Condition: Melanoma
Intervention: Biological: M-Vax- autologous, hapten-modified melanoma vaccine
30 Recruiting A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma
Condition: Stage IV Melanoma
Intervention: Drug: pembrolizumab
31 Recruiting Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma
Condition: Melanoma
Intervention: Biological: tvs-CTL Vaccine
32 Recruiting Intratumoral Injections of LL37 for Melanoma
Condition: Melanoma
Interventions: Biological: LL37;   Other: Photographs
33 Recruiting Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma
Condition: Melanoma
Interventions: Drug: Metformin;   Drug: Melatonin;   Drug: Dacarbazine
34 Recruiting Immunotherapy Study for Patients With Stage IV Melanoma
Conditions: Stage IV Melanoma;   Metastatic Melanoma
Interventions: Drug: HyperAcute®-Melanoma (HAM) Immunotherapy;   Drug: Ipilimumab;   Drug: Pembrolizumab;   Drug: Nivolumab
35 Recruiting A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit
Condition: Metastatic Melanoma
Interventions: Drug: masitinib;   Drug: Dacarbazine
36 Recruiting Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma
Condition: Melanoma
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab
37 Recruiting Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
Condition: Melanoma
Interventions: Drug: Trametinib;   Drug: Dabrafenib
38 Recruiting 18F-FLT PET Imaging in Patients With Advanced Melanoma
Condition: Melanoma
Interventions: Drug: fludeoxyglucose F 18;   Device: Positron emission tomography-computed tomography;   Drug: 18F-fluorothymidine;   Device: Positron emission tomography-magnetic resonance imaging
39 Recruiting Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
Condition: Uveal Melanoma
Interventions: Drug: ipilimumab;   Drug: Nivolumab
40 Recruiting A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Condition: Melanoma
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldeslaukin;   Drug: Pembrolizumab;   Biological: young TIL

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.